CYPHNasdaq

CYPHERPUNK TECHNOLOGIES INC.

Financial Services·Oncology·Phase 2·Cambridge, MA, United States
Oncology

CYPHERPUNK TECHNOLOGIES INC. (CYPH): 2 pipeline candidates · ~26 mo cash runway. Updated within the last hour.

5.4/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway7.1

25.6 months

Financial Health4.9

D/E 0.04 · 79% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider Signal4.3

0 buys · 1 sell (180d)

A transparent, data-derived signal for CYPHERPUNK TECHNOLOGIES INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$83.7M

Cash

$6.7M

Quarterly Burn

$3.4M

Runway

25.6 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2028
Today~28 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
fl-501Preclinical
sirexatamabPhase 2

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

41

Total value held

$8.2M

HolderSharesValue
vanguard capital management llc3,636,828$2.9M
blackrock, inc.2,342,174$1.9M
susquehanna international group, llp1,217,553$963K
renaissance technologies llc725,120$576K
geode capital management, llc571,068$454K
arete wealth advisors, llc12,488$295K
vanguard fiduciary trust co297,086$236K
citadel advisors llc252,100$200K
state street corp140,113$111K
jane street group, llc118,000$94K

Showing top 10 of 41 institutional holders of CYPHERPUNK TECHNOLOGIES INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Douglas E. Onsi J.D.

Frequently asked questions

How many drug candidates are in CYPHERPUNK TECHNOLOGIES INC.'s pipeline?

CYPHERPUNK TECHNOLOGIES INC. (CYPH) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CYPHERPUNK TECHNOLOGIES INC.'s lead drug candidate?

CYPHERPUNK TECHNOLOGIES INC.'s most advanced tracked candidate is fl-501 (Preclinical) for cachexia.

What is CYPHERPUNK TECHNOLOGIES INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CYPHERPUNK TECHNOLOGIES INC. has approximately 25.6 months of cash runway.

What is CYPHERPUNK TECHNOLOGIES INC.'s market capitalization?

CYPHERPUNK TECHNOLOGIES INC.'s market capitalization is approximately $83.7M.

Who is the CEO of CYPHERPUNK TECHNOLOGIES INC.?

Mr. Douglas E. Onsi J.D. is the chief executive officer of CYPHERPUNK TECHNOLOGIES INC. (CYPH).

Get the full picture on CYPHERPUNK TECHNOLOGIES INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.